Discover investment opportunities in Cancer Research Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Cancer Research Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Cancer Research Stocks using our Smart AI Filter.
10 stocks found for "Cancer Research Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.89 | ±41.9% | 22.8 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.83 | ±70.5% | -3.5 | 0.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.63 | ±35.0% | 27.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes MRK an attractive investment for cancer treatment breakthroughs?
A: Merck (MRK) is influential in oncology, particularly with its successful Keytruda drug. Keytruda's approvals for various cancers drive revenue, making MRK appealing for investors seeking growth in cancer treatments.
Q: How does BMY diversify its cancer therapy portfolio?
A: Bristol-Myers Squibb (BMY) offers a diverse oncology portfolio, including immunotherapies like Opdivo and Yervoy. This diversification may reduce risk and enhance appeal to investors eyeing robust pipelines for steady growth.
Q: How does GILD's focus on CAR-T therapy impact its stock profile?
A: Gilead Sciences (GILD), through its acquisition of Kite Pharma, invests heavily in CAR-T therapies. This strategic focus positions GILD in personalized cancer treatment, potentially appealing to investors interested in innovative biotech solutions.
Q: What risks does JNJ face in its oncology segment?
A: Johnson & Johnson (JNJ) faces risks such as regulatory challenges and patent cliffs in its oncology segment. These factors may impact future revenues, requiring investors to remain vigilant about JNJ's pipeline progress.
Q: How does REGN's collaboration with Sanofi influence its cancer research activities?
A: Regeneron Pharmaceuticals (REGN) collaborates with Sanofi on treatments like Libtayo. Collaboration boosts REGN's research capacity, potentially attracting investors interested in biopharmaceutical alliances for competitive advantage.
Q: What distinguishes AMGN in the cancer stock landscape?
A: Amgen (AMGN) distinguishes itself with its innovative biologics and biosimilars, addressing diverse cancer types. Investors may find AMGN's strategy of advancing both new and existing cancer treatments appealing for long-term growth.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more